pim447
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 25, 2012 (NCT01456689)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase PIMINHIBITOR
Serine/threonine-protein kinase PIM inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1- Mol. weight
- 440.47 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3651966 ↗
- ChEMBLCHEMBL3545194 ↗
Also known as
- lgh447
- lgh447
- lgh-447
- lgh-447
- nvp-lgh477
- pim447
- pim447
- pim-447
- pim-447
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02370706 | Phase 1 | May 21, 2015 | Novartis |
| NCT02160951 | Phase 1 | Sep 1, 2014 | Novartis |
| NCT02144038 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2014 | Novartis |
| NCT02078609 | Phase 1 | Mar 20, 2014 | Novartis |
| NCT01456689 | Phase 1 | Apr 25, 2012 | Novartis |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 5 | 5 | 2 | 2012 |
1 organizations
Page 1 / 1